日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.

Nous-209 新抗原疫苗用于预防林奇综合征携带者的癌症:一项 1b/2 期试验。

D'Alise Anna Morena, Willis Jason, Duzagac Fahriye, Hall Michael J, Cruz-Correa Marcia, Idos Gregory E, Thirumurthi Selvi, Ballester Veroushka, Leoni Guido, Garzia Irene, Antonucci Laura, De Marco Lorenzo, Micarelli Elisa, Deng Nan, Seclì Laura, Gogov Sven, Dong Wenli, Jack Lee J, Bowen Charles M, Vornik Lana A, Garcia-Gonzalez Araceli, Reyes-Uribe Laura, Richmond Ellen, Umar Asad, Brown Powel H, Sinha Krishna M, Rodriguez Luz Maria, Scarselli Elisa, Vilar Eduardo

Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses

基于病毒载体的个性化疫苗I期试验可诱导强烈的肿瘤新抗原特异性抗肿瘤T细胞反应

D'Alise, Anna Morena; Leoni, Guido; Cotugno, Gabriella; Siani, Loredana; Vitale, Rosa; Ruzza, Valentino; Garzia, Irene; Antonucci, Laura; Micarelli, Elisa; Venafra, Veronica; Gogov, Sven; Capone, Alessia; Runswick, Sarah; Martin-Liberal, Juan; Calvo, Emiliano; Moreno, Victor; Symeonides, Stefan N; Scarselli, Elisa; Bechter, Oliver

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

首次人体1期研究,评估精氨酸酶抑制剂INCB001158单药或联合帕博利珠单抗治疗晚期或转移性实体瘤患者的疗效

Naing, Aung; Papadopoulos, Kyriakos P; Pishvaian, Michael J; Rahma, Osama; Hanna, Glenn J; Garralda, Elena; Saavedra, Omar; Gogov, Sven; Kallender, Howard; Cheng, LuLu; Smith, Michael; Chen, Xuejun; Kuriakose, Emil; Bauer, Todd

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Linsitinib (OSI-906) 和 Erlotinib 治疗晚期实体瘤患者的 I 期剂量递增研究

Macaulay Valentine M, Middleton Mark R, Eckhardt S Gail, Rudin Charles M, Juergens Rosalyn A, Gedrich Richard, Gogov Sven, McCarthy Sean, Poondru Srinivasu, Stephens Andrew W, Gadgeel Shirish M